Nicotine Addiction - Pipeline Insight, 2024

Nicotine Addiction - Pipeline Insight, 2024

DelveInsight’s, “Nicotine Addiction - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Nicotine Addiction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Nicotine Addiction Understanding

Nicotine Addiction: Overview

Nicotine has been proven to be as addictive as cocaine and heroin and may even be more addictive.

Nicotine Addiction is a common, potentially avoidable consequence of diabetes treatment and a major barrier to better metabolic control in type 1 and type 2 diabetes. It is a significant concern of primary care practitioners and patients when it comes to initiating or intensifying antihyperglycemic therapy.1 Nicotine Addiction can be defined in several ways: by plasma glucose values (biochemical definition), by symptoms (type and severity), and by time of day in which it occurs (daytime or nocturnal).2 The literature is inconsistent in describing biochemical Nicotine Addiction, and these definitions may vary in clinical trials in inpatient versus outpatient settings; thus, an American Diabetes Association (ADA) workgroup has proposed 5 classifications. As Seaquist et al2 have noted, the ADA standard of ≤70 mg/dL (3.9 mmol/L) is an alert value, intended to provide a margin of error for the limited accuracy of glucose monitoring devices at lower glucose levels. Because this value is above the threshold for symptoms, it allows sufficient time for corrective action to be taken.

""Nicotine Addiction - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nicotine Addiction pipeline landscape is provided which includes the disease overview and Nicotine Addiction treatment guidelines. The assessment part of the report embraces, in depth Nicotine Addiction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Nicotine Addiction R&D. The therapies under development are focused on novel approaches to treat/improve in Nicotine Addiction.
• In June 2021, The PEC-Direct Phase 2 study enrolled additional patients to evaluate the safety and efficacy of PEC‑Direct implanted subcutaneously in patients with T1D who have Nicotine Addiction unawareness and/or extreme glycemic lability. Study participants upon enrollment are required to be negative for C-peptide, which is not confounded by exogenous insulin. The Company anticipates reporting additional patient data readouts from the PEC-Direct study in the first half of 2022.

This segment of the Nicotine Addiction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nicotine Addiction Emerging Drugs

• EMB-001: Embera Neuro Therapeutics

EMB-001 is a patented combination product comprised of two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiological responses to stress in addiction.

• NFL-101: NFL Biosciences

NFL-101 is a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. NFL-101 is a natural product based on a standardized extract of tobacco leaf. NFL-101 is delivered via two simple subcutaneous injections, administered one week apart at a Target Quit Date, making patient compliance a breeze. Two additional, optional injections are made available to patients still not abstinent at month three and six.

Further product details are provided in the report……..

Nicotine Addiction: Therapeutic Assessment

This segment of the report provides insights about the different Nicotine Addiction drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Nicotine Addiction

There are approx. 15+ key companies which are developing the therapies for Nicotine Addiction. The companies which have their Nicotine Addiction drug candidates in the most advanced stage, i.e. Phase III include Achieve Life Sciences.

Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Nicotine Addiction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Peptides

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nicotine Addiction: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nicotine Addiction therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nicotine Addiction drugs.

Nicotine Addiction Report Insights

• Nicotine Addiction Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Nicotine Addiction Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Nicotine Addiction drugs?
• How many Nicotine Addiction drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nicotine Addiction?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nicotine Addiction?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Nicotine Addiction and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• CTC Bio
• Omeros
• Antidote Therapeutics
• Achieve Life Sciences
• Respira Technologies
• Mydecine
• Astraea Therapeutics
• Cessation Therapeutics
• Alex Therapeutics
• Embera Neuro Therapeutics
• Novo Nordisk
• Axsome Therapeutics

Key Products

• Varenicline
• OMS405
• ATI-1013
• Cytisinicline
• Nicotine addiction research project
• Psilocybin
• Nicotine addiction Astraea research project
• NicA2 Research Project
• EMB-001
• Eila
• Liraglutide PII
• Bupropion/dextromethorphan